Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma

vg/dog. Post-vaccination monitoring established a lack of adverse effects and confirmed the presence of antigen-specific IFN-γ-producing T cells in the blood of most dogs. Although the variable survival times make it difficult to evaluate the effectiveness of the optimized AAV cancer vaccine at this point, three of the eight dogs were disease-free by the end of study, and two dogs survived 804 and 953 days after vaccination, and one is currently alive. Thus, the optimized AAV cancer vaccine showed promise in a spontaneous cancer animal model that closely recapitulates human disease development.